Medicare's New Hemp Program Is Live

A new physician-supervised pathway, the CMS Substance Access BEI, allows ACOs to provide hemp-derived products to Medicare beneficiaries.

For sleep, the need is urgent: in older adults, untreated sleep problems and the sedatives prescribed for them drive falls, ER visits, and avoidable cost.

‍FloraWorks built TruCBN™ to meet this moment. No other cannabinoid sleep aid brings this level of clinical and safety evidence.

Request Your Cost-Savings Analysis

For medical professionals and ACOs

TruCBN™ is the only hemp-derived sleep ingredient positioned for the BEI program with all of the following:

A completed, peer-reviewed, double-blind, placebo-controlled trial of 1,020 participants.

The 50 mg dose delivered statistically significant improvement in sleep quality versus placebo. All doses outperformed placebo. The 50 mg dose showed the strongest performance when benchmarked against melatonin.
Download the study

A 29-day real-world observational study (n=164)

The study showed that sleep duration increased 38 minutes per night, next-day refreshment improved from 19.95% to 69.61%, and night wakings down from 88.35% to 73.37%. All results statistically significant (p < .05).
Download the study

Comprehensive safety package

Includes 90-day oral toxicity testing, no observed adverse effect level at the highest dose tested, a full genotoxicity package, and supportive human tolerability data from a randomized, placebo-controlled TruCBN™ study.

GMP, ISO 9001, and NSF certifications.

TruCBN™ is a standardized CBN ingredient supported by a comprehensive CMC package, with defined identity, purity, and quality specifications.

Certificate of Analysis on every batch covering potency, pesticides, heavy metals, residual solvents, and microbials.

Want to know more? Download the ACO Evaluation Memorandum

Better sleep. Fewer falls. Less downstream cost.

Under the BEI, ACOs fund products directly at up to $500 per patient per year. Compare that to what poor sleep is already costing your organization in ER visits, hospitalizations, and medication burden.

The data backs this up:

In Medicare populations, untreated insomnia is a meaningful cost driver, associated with substantially higher healthcare costs than matched controls (Wickwire et al., 2019).
In an MSA real-world study, patients over 65 showed a 60% reduction in sleep medication use and a 50% reduction in benzodiazepine daily dose after starting cannabinoid therapy.
Fewer benzodiazepines means fewer falls, fewer ER visits, and fewer hospitalizations.

That is the cost-of-care opportunity TruCBN™ is designed to address.

Request Your Cost-Savings Analysis

The window is open now

Find out how your organization and patient network can benefit from this new program. Begin your implementation process today.
Request Your Cost-Savings Analysis

How to get started

1. Request your Cost-Savings Analysis.

2. We review the cost-of-care opportunity with your team and walk you through the clinical data behind TruCBN™.
‍
3. Build your Implementation Plan. We provide the technical documentation and compliance support to get it submitted.

From submission through audit, FloraWorks supports dosing oversight, adverse event tracking, and the real-world evidence reporting this program requires.

Request Your Cost-Savings Analysis

Request your Cost-Savings Analysis

Tell us about your organization. We will put together a cost-savings analysis and reach out to schedule a review with your team.

Common Questions

If you have a question but don’t see it listed here, please feel free to reach out to us directly at info@flora-works.com.
An optional CMS Innovation Center pathway allowing ACOs to provide eligible hemp-derived products to Medicare beneficiaries under physician supervision, at no cost to patients.
Medicare does not pay for the products. Participating organizations fund them and may retain a portion of resulting savings.
A purified cannabinol (CBN) softgel developed by FloraWorks. It is backed by a peer-reviewed, placebo-controlled human trial (n=1,020) and a full GLP toxicology package—a standard no other CBN ingredient has set.
No. This inquiry is for educational purposes. Availability and clinical appropriateness are determined by participating providers and program requirements.